Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pilot study of teclistamab and talquetamab-based frontline therapy in newly diagnosed high-risk multiple myeloma
2022-000598-15Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teclistamab, talquetamab, daratumumab, bortezomib, lenalidomide and 1 more in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoints: MRD-negative complete response rate after teclistamab plus daratumumab intensification and MRD-negative complete response rate after daratumumab, bortezomib, lenalidomide, and dexamethasone induction. Started Oct 2022; status: active.
02
Drugs
teclistamabtalquetamabdaratumumabbortezomiblenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-000598-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000598-15.